45 results
8-K
EX-99.1
RPTX
Repare Therapeutics Inc
28 Feb 24
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
7:10am
to the satisfaction of the Company's performance obligations for the issuance of the combined licenses and the clinical trial materials transferred. The decrease
8-K
EX-99.1
RPTX
Repare Therapeutics Inc
9 Nov 23
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
7:05am
to the satisfaction of our performance obligations for the issuance of the combined licenses and the clinical trial materials transferred. The decrease
424B5
8ca0j zlfq
4 Aug 22
Prospectus supplement for primary offering
5:00pm
POS AM
qfe70x56w avz7dgn2nr
2 Mar 22
Prospectus update (post-effective amendment)
8:36am
POSASR
EX-5.2
gl5f0ax f4gmyk50y
1 Mar 22
Automatic shelf registration (post-effective amendment)
4:03pm
POSASR
gbbxcipj2n9144ihs h7
1 Mar 22
Automatic shelf registration (post-effective amendment)
4:03pm
424B5
gr49 oi7c1d
28 Oct 21
Prospectus supplement for primary offering
5:27pm
424B5
4qjpienlwfgf589eo
27 Oct 21
Prospectus supplement for primary offering
4:54pm
S-3ASR
EX-4.9
x0s70piyao7axgvunlvx
2 Jul 21
Automatic shelf registration
4:47pm
S-3ASR
vp6nur 3occi8i424jvw
2 Jul 21
Automatic shelf registration
4:47pm